Odiparcil - Inventiva Pharma

Drug Profile

Odiparcil - Inventiva Pharma

Alternative Names: 424323; IVA336; SB 424323

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fournier Pharma
  • Developer Fournier Pharma; GlaxoSmithKline; Inventiva Pharma; Solvay
  • Class Antithrombotics; Glycosides; Small molecules
  • Mechanism of Action Glycosaminoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VI
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mucopolysaccharidosis VI
  • Discontinued Atrial fibrillation; Deep vein thrombosis; Stroke; Thrombosis

Most Recent Events

  • 15 May 2018 Inventiva Pharma expects to receive a rare paediatric disease designation for Mucopolysaccharidosis VI by the US FDA in third quarter of 2018
  • 15 May 2018 Inventiva Pharma plans the phase Ib SAFE-KIDDS (SAFEty, pharmacoKInetics and pharmacoDynamics, Dose escalating Study) trial for Mucopolysaccharidosis VI (In children) in second half of 2018
  • 13 Apr 2018 Inventiva plans a phase Ib trial in Mucopolysaccharidosis VI (In children)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top